Particularly, PHD1 inhibition or HIF-1α activity increase are thought to be effective treatments for IBD; conversely, PHD3 activity decrease or HIF-2α stability enhancement may have detrimental effects on IBD. The gene discussed is EGLN2; the disease is inflammatory bowel disease.